Stage III Verrucous Carcinoma of the Larynx Completed Phase Trials for DB00317 (Gefitinib)

IndicationStatusPhase
DBCOND0029516 (Stage III Verrucous Carcinoma of the Larynx)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment